What the evidence shows so far

For patients with a focal hip cartilage defect, the most pressing question is straightforward: does a ChondroFiller injection work, and will the benefit last?

The most informative hip-specific data come from a prospective cohort published in the Journal of Hip Preservation Surgery in 2021 (Roszak et al.). Twenty-six adults with femoroacetabular impingement (FAI) and acetabular cartilage lesions larger than 2 cm² were treated and followed for between one and five years. Of the 21 patients who reached evaluable follow-up, 17 — just over 80% — achieved good or excellent outcomes on MRI-confirmed cartilage healing assessments. That is a meaningful signal, particularly given the defect sizes involved and the length of follow-up.

It is important to note that this study used arthroscopic delivery of ChondroFiller gel, which represents an earlier, theatre-based route. The current outpatient service pathway delivers ChondroFiller as an ultrasound-guided injection — a less invasive approach that does not require arthroscopy or general anaesthesia. The Roszak findings are therefore best understood as external research context rather than a description of how ChondroFiller is administered today.

The two patients in that cohort who required conversion to total hip replacement both had advanced pre-existing osteoarthritis, graded Tönnis 2–3. This pattern is consistent across hip cartilage repair evidence more broadly: the treatment is designed for isolated focal defects in a joint that is otherwise reasonably preserved — not for diffuse or late-stage arthritis. Who is and is not a suitable candidate matters considerably, and that is explored in the next section.

Which patients are likely to benefit

The typical candidate is a young to middle-aged adult in whom femoroacetabular impingement — particularly CAM-type FAI, where a bony prominence on the femoral head abrades the acetabular lining — has produced a localised patch of cartilage damage. Because the injury is focal rather than spread across the joint surface, a scaffold injection can target the affected area while the surrounding cartilage remains viable.

The Tönnis grading system offers a useful shorthand for the degree of underlying arthritis, scored from 0 (no radiological changes) to 3 (severe joint space collapse). ChondroFiller injection is best suited to patients at Tönnis grade 0 or 1 — minimal or no established arthritis — where the joint environment supports tissue regeneration. At grade 2 or 3, the structural changes are too widespread for a focal scaffold to address meaningfully, and the appropriate conversation shifts toward hip preservation or replacement planning.

Defect size is a further practical boundary: ChondroFiller is formulated for focal lesions, typically up to 3 cm² and extendable to 6 cm² in selected cases. Diffuse cartilage loss falls outside its scope.

No patient should assume they qualify without proper imaging. An MRI or CT arthrogram is usually necessary to confirm lesion grade, size, and the condition of the surrounding joint before any treatment recommendation can be made.

How MOCART scoring measures cartilage fill on MRI

Think of MOCART — Magnetic Resonance Observation of Cartilage Repair Tissue — as a radiologist's report card for how well repair tissue is growing back into a cartilage defect. The score runs from 0 to 100, where 100 would represent perfect, hyaline-like cartilage filling the defect completely; in practice, scores in the 75–90 range indicate well-integrated, near-complete fill, whilst anything below 60 suggests incomplete healing or poor tissue integration.

Six parameters make up the total: degree of defect fill, how well the repair tissue integrates with the adjacent native cartilage, surface regularity, signal intensity on MRI (which distinguishes hyaline-like cartilage from inferior fibrocartilage), and the condition of the underlying subchondral bone plate. Each parameter contributes to the overall picture of tissue quality.

Crucially, MOCART is designed for serial use. Assessments at 12, 24, and 36 months reveal whether repair tissue is maturing progressively — ongoing improvement over that window is a positive sign, quite different from a one-time snapshot. In hip cartilage repair studies, MRI with MOCART assessment is the standard structural monitoring tool across that timeframe.

MOCART measures structure, not symptoms. Clinicians therefore read it alongside patient-reported outcome scores such as iHOT33 or the modified Harris Hip Score (mHHS) to form a complete picture of how a patient is recovering.

MOCART benchmarks for hip cartilage repair at 12–36 months

Published MOCART figures for ChondroFiller exist only for knee cartilage studies — no equivalent hip-specific imaging dataset has been reported. Those knee results nonetheless carry weight as a structural proxy, because the collagen scaffold biology is the same regardless of the joint involved. Across four European clinical studies, scores range from 81.6 to 84.3 at 12 months, reflecting more than 80% defect fill with good integration into surrounding native cartilage. The trajectory matters as much as the endpoint: the mean score at four weeks stands at 65.3, rising to 81.6 by twelve months — clear evidence that repair tissue continues to mature well beyond the initial gelling and early colonisation phase.

For context grounded in the hip joint specifically, two published comparator datasets are instructive. A 2023 study of injectable matrix-associated chondrocyte transplantation (NOVOCART® Inject) in FAI patients reported complete MRI defect filling in 11 of 14 evaluable patients at 24 months, alongside iHOT33 rising from 52.9 to 85.8 (p<0.0001). Autologous minced cartilage implantation in acetabular defects achieved a mean MOCART of 87.2 (±9.2) at two years, with iHOT-12 improving from 50.2 to 86.5 (p<0.0001). Taken together, these hip-specific datasets place well-performed focal cartilage repair in the 75–87 MOCART range across 12–36 months — and that range is where ChondroFiller's scaffold biology, given its documented maturation curve and comparable fill scores in the knee, lands on current evidence.

Why repair tissue continues to mature after the injection

The scaffold doesn't regenerate cartilage independently — it creates the right environment for the patient's own progenitor cells to do that work. Once injected into the defect, the collagen gel acts as a chemotactic matrix: mesenchymal progenitor cells migrate into it from surrounding tissue and synovial fluid. Ex vivo measurement of DNA content within osteochondral explants found a 2.4-fold increase by day 14, confirming that active cell colonisation begins rapidly. Those cells then deposit glycosaminoglycans (GAG) and new collagen — the molecular building blocks of cartilage — which is why the repair tissue becomes progressively more cartilage-like over months rather than weeks. The 12–36-month window reflects a well-characterised biological process, not an arbitrary waiting period.

In the hip specifically, the joint's principal load-bearing role adds a practical dimension to this timeline. Biomechanical in vitro testing found that an immature collagen gel does not adequately protect the opposing articular surface under full cyclic loading; the material's early-phase instability means the joint benefits from partial offloading until stable defect fill is established. Rehabilitation after a ChondroFiller injection therefore follows a graduated weight-bearing protocol, and that approach is grounded directly in the scaffold's maturation biology.

The low procedural burden of the injectable pathway is matched by its safety record. Requiring no cell harvest, no general anaesthesia, and no theatre time, the acellular scaffold carries an approximately 0% reported complication rate and a reoperation rate of 3–8%. Those figures compare favourably with microfracture, where reoperation rates reach up to 41%, and with ACI/MACI, where they can approach 37% — a difference that is practically relevant for hip patients hoping to avoid further intervention.

What the evidence does not yet tell us — and realistic expectations

Three gaps deserve plain acknowledgement, because naming them honestly makes the data that do exist more credible, not less.

No hip-specific MOCART figures for ChondroFiller injection. Every MOCART score cited in this article derives from knee studies. The biological reasoning for treating those figures as a structural proxy is sound — the scaffold is joint-agnostic — but a dedicated hip imaging dataset has not been published. That is the single most important limitation on current evidence.

A small, uncontrolled cohort. The Roszak et al. 2021 series — 26 enrolled, 21 evaluable — is the best available hip-specific evidence and its 12–60-month results are encouraging. It is not a randomised controlled trial, and the absolute numbers are modest. Two patients required conversion to total hip replacement; three were lost to follow-up.

Functional scores beyond the categorical rating. The 17-of-21 good-or-excellent result is clinically meaningful. Validated hip-specific outcome scores — iHOT-33 or Harris Hip Score tracked over time — have not been published for this cohort. The comparator injectable MACT study did report iHOT33 rising from 52.9 to 85.8 at 24 months, establishing what a strong functional response looks like in the hip joint; equivalent figures for ChondroFiller injection remain unpublished.

Against those limitations, what can be said with confidence is this: the hip cohort outcomes at 12–60 months are genuinely encouraging, the scaffold biology is well-characterised, and no head-to-head injectable comparator study has overturned that picture. For any patient weighing this pathway, the practical implication is that imaging-guided assessment — confirming defect grade, size, and overall joint background — is the necessary first step before any treatment decision can be made. Lincolnshire Hip accepts patients without a GP referral for that initial hip assessment and is part of the MSK Doctors group.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
3. [3] Minced Cartilage Implantation in Acetabular Cartilage Defects: Case Series with 2-Year Results. (2023). https://doi.org/10.1177/19476035231189840 https://doi.org/10.1177/19476035231189840
4. [4] Acetabular cartilage lesions predict inferior mid-term outcomes for arthroscopic labral repair and FAIS treatment. (2022). https://doi.org/10.1016/j.arthro.2022.05.013 https://doi.org/10.1016/j.arthro.2022.05.013
5. [5] Microfracture of Acetabular Chondral Lesions is Not Superior to Other Cartilage Repair Techniques in Patients with FAIS: A Systematic Review. (2023). https://doi.org/10.1016/j.arthro.2023.05.034 https://doi.org/10.1016/j.arthro.2023.05.034
6. [6] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
7. [7] Development of an Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration — ChondroFiller® group findings. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759